ରୁକାପାରିବ

ରୁକାପାରିବ
Clinical data
Pronunciation	/ruːˈkæpərɪb/ ROO-KAP-ƏR-ib
Trade names	Rubraca
Synonyms	AG014699
AHFS/Drugs.com	monograph
MedlinePlus	a617002
data	US DailyMed: Rucaparib;
Pregnancy; category	US: N (Not classified yet) ; Not recommended;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	30–45% (Tmax = 1.9 hours)
Protein binding	70% (in vitro)
Metabolism	Liver (primarily CYP2D6; 1A2 and 3A4 to a lesser extent)
Elimination half-life	17–19 hours
Identifiers
	IUPAC name 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one;
ECHA InfoCard	100.247.490
Chemical and physical data
Formula	C19H18FN3O
Molar mass	୩୨୩.୩୭ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34;
	InChI InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24); Key:HMABYWSNWIZPAG-UHFFFAOYSA-N;

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Rucaparib

ରୁକାପାରିବ (ଇଂରାଜୀ ଭାଷାରେ Rucaparib), ରୁବ୍ରାକା ବ୍ରାଣ୍ଡ ନାମରେ ବିକ୍ରି ହେଉଛି, ଏକ ଔଷଧ ଯାହା ଓଭାରି କର୍କଟ, ଫାଲୋପିଆନ୍ ଟ୍ୟୁବ୍ କର୍କଟ, ପେରିଟୋନିଆଲ୍ କର୍କଟ ଏବଂ ପ୍ରୋଷ୍ଟେଟ୍ କର୍କଟ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ^[୩] ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସା ବିଫଳ ହେଲେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥକ୍କା, ଅଇ, ବୃକ୍‌କ ସମସ୍ୟା, ଯକୃତ ସମସ୍ୟା, ସ୍ୱଳ୍ପ ଲୋହିତ ରକ୍ତ କଣିକା, ଅସ୍ୱାଭାବିକ ସ୍ୱାଦ, ତରଳ ଝାଡ଼ା, କମ୍ ରକ୍ତ ପ୍ଲାଟେଲେଟ୍ ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତୀବ୍ର ମାୟେଲଏଡ ଲିଉକେମିଆ ଏବଂ ସ୍ୱଳ୍ପ ରକ୍ତ ନିଉଟ୍ରୋଫିଲ୍ ହୋଇପାରେ । ^[୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୫] ଏହା ଏକ ଆରଏଆରପି (PARP) ନିଷ୍କ୍ରିୟକାରୀ, ଯାହାକି ବିଆରସିଏ (BRCA) ଜିନ ପରିବର୍ତ୍ତନ ସହିତ କୋଷଗୁଡ଼ିକରେ ଡିଏନଏ ମରାମତିକୁ ଅବରୋଧ କରିଥାଏ ।^[୨]

୨୦୧୬ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଏବଂ ୨୦୧୮ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ରୁକାପାରିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୫] ^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ପିଛା ମାସକୁ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରାୟ ୯,୧୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହେଉଥିଲା ।^[୬]

ଆଧାର[ସମ୍ପାଦନା]

↑ "Rubraca 200mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Archived from the original on 29 August 2021. Retrieved 17 May 2020.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "DailyMed - RUBRACA- rucaparib tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 9 May 2020. Retrieved 19 October 2021.
↑ "Rucaparib Camsylate - National Cancer Institute". www.cancer.gov (in ଇଂରାଜୀ). 3 January 2017. Archived from the original on 9 July 2021. Retrieved 19 October 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ "Rubraca". Archived from the original on 6 August 2020. Retrieved 19 October 2021.
↑ ^୫.୦ ^୫.୧ ^୫.୨ "Rucaparib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 19 October 2021.
↑ "Rubraca Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 20 March 2021. Retrieved 19 October 2021.

[1] "Rubraca 200mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Archived from the original on 29 August 2021. Retrieved 17 May 2020.

[PI2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "DailyMed - RUBRACA- rucaparib tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 9 May 2020. Retrieved 19 October 2021.

[NCI2021-3] "Rucaparib Camsylate - National Cancer Institute". www.cancer.gov (in ଇଂରାଜୀ). 3 January 2017. Archived from the original on 9 July 2021. Retrieved 19 October 2021.

[EPAR2021-4] ୪.୦ ^୪.୧ ^୪.୨ "Rubraca". Archived from the original on 6 August 2020. Retrieved 19 October 2021.

[AHFS2021-5] ୫.୦ ^୫.୧ ^୫.୨ "Rucaparib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 19 October 2021.

[6] "Rubraca Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 20 March 2021. Retrieved 19 October 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]